Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2022 - 2025)

Historic Interest & Investment Income for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $1.4 million.

  • Phathom Pharmaceuticals' Interest & Investment Income fell 6192.4% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 3765.0%. This contributed to the annual value of $15.2 million for FY2024, which is 9245.81% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Interest & Investment Income is $1.4 million, which was down 6192.4% from $1.8 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Interest & Investment Income high stood at $4.3 million for Q1 2024, and its period low was $7000.0 during Q1 2022.
  • Moreover, its 4-year median value for Interest & Investment Income was $1.8 million (2025), whereas its average is $2.1 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Interest & Investment Income skyrocketed by 2075714.29% in 2023, and later plummeted by 6192.4% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Interest & Investment Income stood at $1.3 million in 2022, then soared by 160.14% to $3.3 million in 2023, then grew by 4.84% to $3.5 million in 2024, then tumbled by 59.74% to $1.4 million in 2025.
  • Its Interest & Investment Income stands at $1.4 million for Q3 2025, versus $1.8 million for Q2 2025 and $2.6 million for Q1 2025.